Knight Therapeutics Inc.
KHTRF
$6.96
$0.192.81%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -4.87% | 11.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.87% | 11.80% | |||
| Cost of Revenue | -7.93% | 16.30% | |||
| Gross Profit | -1.37% | 7.04% | |||
| SG&A Expenses | 4.13% | -2.60% | |||
| Depreciation & Amortization | -10.18% | 6.31% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.94% | 8.91% | |||
| Operating Income | -17.06% | 70.76% | |||
| Income Before Tax | -114.52% | 26.67% | |||
| Income Tax Expenses | 21.61% | -57.15% | |||
| Earnings from Continuing Operations | -124.99% | 49.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -124.99% | 49.11% | |||
| EBIT | -17.06% | 70.76% | |||
| EBITDA | -12.34% | 62.94% | |||
| EPS Basic | -125.05% | 50.55% | |||
| Normalized Basic EPS | -54.38% | 897.18% | |||
| EPS Diluted | -125.78% | 46.32% | |||
| Normalized Diluted EPS | -54.12% | 891.55% | |||
| Average Basic Shares Outstanding | -0.26% | -0.89% | |||
| Average Diluted Shares Outstanding | -0.74% | -0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||